Oliver J. McElvaney

TL;DR: The COVID-19 cytokinemia is distinct from that of other types of pneumonia, leading to organ failure and ICU need, and Cytokine ratios may predict outcomes in this population.

TL;DR: It is demonstrated using human neutrophils that serum AAT coordinates both CXCR1- and soluble immune complex (sIC) receptor-mediated chemotaxis by divergent pathways, and new insight is provided into the mechanism underlying the effect of AAT augmentation therapy in the pulmonary disease associated with AAT deficiency.

TL;DR: It is illustrated that disrupted function of the CF transmembrane conductance regulator (CFTR), such as that which occurs in patients with ∆F508 and/or G551D mutations, correlates with impaired degranulation of antimicrobial proteins and intrinsic alterations of circulating neutrophils from patients with CF are corrected by ivacaftor, thus illustrating additional clinical benefits for CFTR modulator therapy.

TL;DR: The role of interleukin-6 in health and disease, explain the different types of IL-6 signalling and their contribution to the net biological effect of the cytokine, describe the approaches to IL6 inhibition that are currently available, and discuss implications for the future use of treatments such as tocilizumab in the critical care setting.

TL;DR: The relationship between the ratio of interleukin (IL)-6 to IL-10 and clinical outcome in 80 patients hospitalized for COVID-19 was studied, and a simple 5-point linear score predictor of clinical outcome was created, the Dublin-Boston score.